1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,252 | 0,317 | 20.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.05. | AcouSort AB: AcouSort AB - Interim Report for the period January - March 2026 | 147 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037.
First quarter 2026 for the GroupNet sales amounted to TSEK 2,147 (1,595)Result before tax amounted... ► Artikel lesen | |
| 10.03. | AcouSort AB: AcouSort receives prepayment of royalties | 287 | GlobeNewswire (Europe) | AcouSort AB today announced the signing of an amendment to its license and distribution agreement with the leading blood-gas analyzer company, Werfen. Under the amendment, Werfen will prepay minimum... ► Artikel lesen | |
| 25.02. | AcouSort AB: Year end report for AcouSort AB 1 January - 31 December 2025 | 202 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037.October - December 2025 for the GroupNet sales amounted to TSEK 2,459 (1,221)Result before tax... ► Artikel lesen | |
| 19.12.25 | AcouSort AB: AcouSort and MFX enter a collaboration to streamline future cell therapy manufacturing | 1.171 | GlobeNewswire (Europe) | AcouSort AB today announced it has entered a collaboration with MFX, a UK-based developer of next-generation scalable bioreactor platforms, to evaluate if AcouSort's technology can be paired with MFX's... ► Artikel lesen | |
| 15.12.25 | AcouSort AB: Stefan Blomsterberg elected new Chairman of the Board of AcouSort | 251 | GlobeNewswire (Europe) | AcouSort AB today announced that Stefan Blomsterberg has been appointed new Chairman of the Board, effective January 1, 2026.
Stefan Blomsterberg currently holds the position as CEO of CELLINK Bioprinting... ► Artikel lesen | |
| 26.11.25 | AcouSort AB: AcouSort AB - Interim Report for the period January - September 2025 | 238 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037.
July - September 2025 for the GroupNet sales amounted to TSEK 1,248 (1,198)Result before tax... ► Artikel lesen | |
| ACOUSORT Aktie jetzt für 0€ handeln | |||||
| 19.11.25 | AcouSort AB: AcouSort and Danish SeeQ Diagnostics sign technology evaluation agreement | 399 | GlobeNewswire (Europe) | AcouSort AB today announced it has signed a technology evaluation agreement with the Danish diagnostics company SeeQ Diagnostics concerning the evaluation of AcouSort's blood/plasma separation technology... ► Artikel lesen | |
| 22.09.25 | AcouSort AB: AcouSort receives new order boosting Central European collaboration | 243 | GlobeNewswire (Europe) | AcouSort AB today announced it has received a third order from a Central European company that develops diagnostic systems and medical devices. The company evaluates AcouSort's novel technology for... ► Artikel lesen | |
| 27.08.25 | AcouSort AB: AcouSort AB - Interim Report for the period January - June 2025 | 214 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037.
April - June 2025 for the GroupNet sales amounted to TSEK 1,551 (961)Result before tax amounted... ► Artikel lesen |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 60,40 | -0,10 % | Novonesis Q2 Profit Rises | BRUSSELS (dpa-AFX) - Novonesis (NVZMF.PK) released earnings for its second quarter that Increases, from the same period last yearThe company's bottom line came in at EUR171.7 million, or EUR0.37... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,656 | +4,59 % | 'We're not afraid of competition': BioCryst CEO sets out strategy after scrapping internal discovery | ||
| SARTORIUS STEDIM BIOTECH | 194,60 | +0,31 % | AKTIE IM FOKUS: Kaufempfehlungen treiben Sartorius und Stedim Biotech an | FRANKFURT/PARIS (dpa-AFX) - Die Aktien von Sartorius und ihrer französischen Tochter Sartorius Stedim Biotech haben am Donnerstag von Kaufempfehlungen der UBS profitiert. Für Sartorius Vorzugsaktien... ► Artikel lesen | |
| BIOLIFE SOLUTIONS | 31,200 | +4,70 % | BioLife Solutions, Inc.: BioLife Solutions Reports Second Quarter 2026 Financial Results | Total revenue of $28.5 million, up 21% over Q2 2025
GAAP gross margin of 64% and non-GAAP adjusted gross margin of 65%
GAAP net income of $45.1 million, inclusive... ► Artikel lesen | |
| ADMA BIOLOGICS | 9,760 | 0,00 % | Kehoe Law Firm, P.C.: ADMA Biologics (ADMA) Shareholder Alert: Kehoe Law Firm Investigates Potential Fiduciary Duty Breaches | Philadelphia, Pennsylvania--(Newsfile Corp. - August 5, 2026) - Kehoe Law Firm, P.C. is investigating whether certain officers and directors of ADMA Biologics, Inc. ("ADMA," "ADMA Biologics," or... ► Artikel lesen | |
| CRESCENT BIOPHARMA | 14,000 | +3,70 % | Crescent Biopharma, Inc.: Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights | Enrollment progressing in ASCEND Phase 1/2 global clinical trial evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients CR-001... ► Artikel lesen | |
| MODERNA | 113,70 | -0,37 % | BREAKING: AKTIONÄR-Depotwert Moderna explodiert! | Ein Durchbruch der mRNA-Technologie im Bereich der Onkologie: Moderna und der Entwicklungspartner Merck & Co haben die lang ersehnten ersten Ergebnisse der Phase-3-Studie INTerpath-001 mit Intismeran... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 39,640 | -0,05 % | Kaum zu fassen: Die unglaubliche Biotech-Story von Amylyx Pharmaceuticals | Der Biotech-Sektor ist immer wieder für faustdicke Überraschungen gut - sowohl negativ als auch positiv. Bei Amylyx Pharmaceuticals gibt es am Dienstag keine zwei Meinungen: Die Aktie des Biotech-Unternehmens... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 78,47 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| QIAGEN | 38,735 | +3,05 % | DAX Gewinner am Mittwoch: Qiagen Aktie | Kursentwicklung und Chartanalyse | ||
| BIONTECH | 94,80 | -0,16 % | Schlafender Biotech-Riese vor der nächsten Wachstumsphase? BioNTech, Emyria und die neue Macht der Datenplattformen | ||
| PRAXIS PRECISION MEDICINES | 364,38 | -0,05 % | Raymond James raises Praxis Precision Medicines price target on pipeline outlook | ||
| APOGEE THERAPEUTICS | 134,78 | +0,02 % | AbbVie schließt Anleiheemission über 8,0 Mrd. US-Dollar zur Finanzierung der Übernahme von Apogee Therapeutics ab | ||
| NURIX THERAPEUTICS | 27,050 | 0,00 % | Biotech Stocks At 52-Week Highs - DCTH +22% On Q2 Results, ANRO, COAG, MNPR, NRIX | SOUTH SAN FRANCISCO (dpa-AFX) - The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming conference participation.... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 25,360 | +0,04 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen |
Das Unternehmen ACOUSORT AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -2,26 % bei einem Aktienkurs von 0,260 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACOUSORT AB finden Sie auf Wallstreet Online.